You are here
Bladder
Bladder knowledge base with publications, presentations, webcasts and more.
General Bladder Cancer
This section includes studies on:
- Validating markers for bladder cancer: diagnosis and prognosis, screening and markers of prediction of response to therapies (endovesical or systemic therapies)
- Epidemiological factors in bladder cancer
- New tools for imaging diagnosis in bladder cancer
Latest Headlines
Performance Characteristics of a Multigene Urine Biomarker Test for Monitoring for Recurrent Urothelial Carcinoma in a Multicenter Study
Kavalieris L, O'Sullivan P, Frampton C, Guilford P, Darling D, Jacobson E et al.
06/09/2017Editorial comment from Piotr Chlosta:
A novel noninvasive multigene urine biomarker test for the surveillance of bladder cancer recurrence, The Cxbladder Monitor, offers high sensitivity and high negative predictive value for ruling out urothelial carcinoma. Results suggest potential for deferring or avoiding cystoscopy in bladder cancer patients.Effect of contrast media on urinary cytopathology specimens
S. Frees, S. Bidnur, M. Metcalfe, P. Raven, C. Chavez-Munoz, I. Moskalev, et al.
02/27/2017Editorial comment from Piotr Chlosta:
Study suggests that commonly used contrast agents do not alter urothelial cell morphology and do not impair cytopathological analysis when fixation is within 5 minutes following exposure, questioning common recommendation of collecting washings from urinary tract before contrast agent administration.
Muscle Invasive Bladder Cancer (MIBC)
This section considers studies on:
- New systemic therapies for muscle invasive bladder cancer (metastatic or complementary therapies to cystectomy)
- The role of lymphadenectomy in muscle invasive bladder cancer
- Indications for bladder preservation in muscle invasive bladder cancer
- Role of metastatectomy on muscle invasive bladder cancer
- New techniques for cystectomy
Latest Headlines
Patterns of Bladder Preservation Therapy Utilization for Muscle-Invasive Bladder Cancer
Rose TL, Deal AM, Ladoire S, Créhange G, Galsky MD, Rosenberg JE, et al.
04/19/2017Editorial comment from Piotr Chlosta:
In clinical practice, BPT patients have similar survival to RC patients when treated with curative radiotherapy doses. Choice of concurrent chemotherapy regimen varied widely with no clear standard.Muscle-invasive bladder cancer: Molecular subtypes and response to neoadjuvant chemotherapy
R. Seiler, B. Winters, J. Douglas, B. van Rhijn, G. Sjödahl, S. Lerner, et al.
03/30/2017Editorial comment from Prof. Piotr Chlosta:
Benefit of cisplatin based neoadjuvant chemotherapy varied depending on molecular subtype of bladder cancer. NAC (compared to surgery alone) was associated with improvement in prognosis in basal subtype, while there was no improvement for other subtypes. Results suggest that molecular subtyping may help in selecting patients who could benefit most from NAC, and patients who could be best managed with surgery alone.Incidence, Characteristics and Implications of Thromboembolic Events in Patients with Muscle Invasive Urothelial Carcinoma of the Bladder Undergoing Neoadjuvant Chemotherapy
Duivenvoorden WC, Daneshmand S, Canter D, Lotan Y, Black PC, Abdi H, et al.
02/01/2017Editorial comment from Piotr Chlosta: The overall incidence of thromboembolic events (TEEs) in patients undergoing neoadjuvant chemotherapy before radical cystectomy was 14%, with 58% of events occurring preoperatively. Prophylaxis to prevent TEEs may need to be initiated earlier in these patients, during the NAC treatment course.
Non Muscle Invasive Bladder Cancer (NMIBC)
This section includes studies on:
- New endovesical therapies for non muscle invasive bladder cancer
- New approaches for high-risk non muscle invasive bladder cancer
- Transurethral resection of bladder tumour (TURBT) techniques and new tools for imaging diagnosis non muscle invasive bladder cancer
Latest Headlines
Suppressed Recurrent Bladder Cancer after Androgen Suppression with Androgen Deprivation Therapy or 5α-Reductase Inhibitor
Shiota M, Kiyoshima K, Yokomizo A, Takeuchi A, Kashiwagi E, Dejima T, et al.
02/27/2017Editorial comment from Piotr Chlosta:
Study suggests that androgen suppression therapy may have prophylactic effect on intravesical recurrences in NMIBC patients. Further investigations are warranted.
EAU 2017 Scientific Programme and Sessions
View the Scientific Programme and Sessions of the 2017 EAU Annual Congress, Munich, Germany.
E-Alert
Subscribe to our E-Alert to keep up to date with the new items in the Resource Centre
URO ONCO is made possible by an unrestricted educational grant from:
The editorial independence of the resource centre is mandatory and recognized by the EAU and Elsevier.
The journal articles, videos and statements published on the resource centre have been selected independently and without influence from Elsevier, European Urology Editors or the sponsor and do not necessarily reflect their opinions or views.
Editorial comment from Piotr Chlosta: Retrospective analysis of early recurrences in 717 patients undergoing totally intracorporeal robot-assisted radical cystectomy (RARC) in nine centers showed recurrence patterns similar to those reported for open radical cystectomy series.